Formulation; HIV prevention; Preclinical testing; Rectal microbicide; Safety
Indexed keywords
GLYCEROL;
MICROBICIDE;
TENOFOVIR;
ANTIVIRAL ACTIVITY;
ARTICLE;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG SAFETY;
EPITHELIUM CELL;
GAS PERMEABILITY;
GEL;
HUMAN;
HUMAN CELL;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
HUMAN TISSUE;
IN VITRO STUDY;
OSMOLALITY;
ADENINE;
ANTI-HIV AGENTS;
ANTI-INFECTIVE AGENTS;
DISEASE TRANSMISSION, INFECTIOUS;
FEMALE;
HIV INFECTIONS;
HIV-1;
HUMANS;
ORGAN CULTURE TECHNIQUES;
ORGANOPHOSPHONATES;
RECTUM;
TREATMENT OUTCOME;
VAGINA;
VAGINAL CREAMS, FOAMS, AND JELLIES;
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
Per-contact risk of human immunodeficiency virus transmission between male sexual partners
Vittinghoff E, Douglas J, Judson F et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150: 306-11.
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women
Mayer KH, Maslankowski LA, Gai F et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20: 543-51.
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide
Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE 2010; 5: e9310.
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission
Fuchs EJ, Lee LA, Torbenson MS et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis 2007; 195: 703-10.
Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations
Wang L, Schnaare RL, Dezzutti C et al. Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations. AIDS Res Ther 2011; 8: 12.
The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention
Boily MC, Dimitrov D, Abdool Karim SS et al. The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sex Transm Infect 2011; 87: 646-53.
RMP-02/MTN-006: a Phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF
Abstract #Y-1025. Foundation for Retrovirology and Human Health, Alexandria, VA, USA
Anton P, Cranston R, Carballo-Dieguez A et al. RMP-02/MTN-006: a Phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Abstract #Y-1025. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
First Phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
Anton PA, Saunders T, Elliott J et al. First Phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS ONE 2011; 6: e23243.